Biomarker can exclude acute kidney injury

"The biovariability of a biomarker is a key attribute, but not tested for many of the novel kidney markers. penKid shows a low variability – allowing information with the first measurement," said Dr. Wu. "penKid has a huge value to rule out patients in EDs," confirmed Prof. Salvatore Di Somma, Head of Emergency Medicine Sant’Andrea Hospital, Rome, Italy. sphingotec also showed data from pilot routine testing, which has already begun at undisclosed ICUs and EDs in Germany. Study leaders confirmed that triaging will be supported by penKid information, because the marker can rule out AKI as BNP rules out Heart Failure. 

Plasma penKid is a surrogate marker for disturbed renal glomerular filtration rate (GFR), which reflects kidney function. Previous studies on more than 30,000 critically ill patients admitted to EDs or ICUs with congestive heart failure or sepsis demonstrated that penKid levels change dynamically with the actual kidney function independently from comorbidities or inflammation. penKid levels rise up to 48 hours prior to those of creatinine preceding kidney injury (AKI).

sphingotec said that it will launch a penKid point-of-care (POC) test running on its fully automated Nexus IB10 POC testing platform for use in EDs and ICUs by the end of H1/2019 The platform allows measurement of up to five critical care biomarker tests in one run within 20 minutes without any sample preparation.